Hyundai Motor Way
Scope
Date
~
-
Hyundai Investments seeks to raise up to €200 million for BC Partners’ buyout fund
Hyundai Investments Co. Ltd., wholly owned by Hyundai Marine & Fire Insurance Co. Ltd., is seeking to raise between €100 million ($107 million) an...
Apr 20, 2017 (Gmt+09:00)
-
[Interview] Hyundai Marine sees one or two more buyout fund investments in 2017
Hyundai Marine & Fire Insurance Co. Ltd., South Korea’s second-largest non-life insurer by assets, is considering investing in one or two addition...
Feb 21, 2017 (Gmt+09:00)
-
Hyundai Marine to be anchor investor of Allianz’s new Berlin office tower: report
South Korea’s Hyundai Marine & Fire Insurance Co. Ltd. will commit around 60 billion won and 70 billion won ($50~58 million) to a domestic real es...
Jan 11, 2017 (Gmt+09:00)
-
Tech, Media & Telecom
SPIKE. NO EDIT HERE. Hyundai Motor Group to adopt digital twin technology
Hyundai Motor Group plans to adopt digital twin, a technology that allows the automaker to make a digital replica of a real car for simulation not...
1 MINUTES AGO
-
SK Innovation to supply batteries to Hyundai’s IONIQ 7
SK Innovation Co. is set to supply batteries for the IONIQ 7, Hyundai Motor Co.’s large electric sport utility vehicle (SUV) to be unveiled in...
1 MINUTES AGO
-
-
Shipping & Shipbuilding
Hyundai's first Saudi JV shipyard slated for 2023 completion
South Korea's Hyundai Heavy Industries Holdings Co. is scheduled to construct a large-scale shipyard for very large crude carriers (VLCCs) and a mar...
1 MINUTES AGO
-
Hyundai Mobis
Hyundai Mobis Co., the world’s sixth-largest automotive parts maker, known as Mobis outside of South Korea, has set its sights on another stro...
1 MINUTES AGO
Latest News
- 1 Google to invest $100 mn in Gentle Monster in smart glasses push
- 2 Growth equity portfolio largely shielded from policy headwinds: Summit
- 3 Naver Financial seeks to acquire S. Korean real estate data platform Asil
- 4 KakaoBank shares surge on Thai virtual bank approval
- 5 Lotte Biologics signs antibody drug CMO deal with UK’s Ottimo Pharma